Navigation Links
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Date:8/6/2009

severe hypercholesterolemia patients should be available at the time of these U.S. submissions and may provide the basis for a broader indication. A potential second filing in Europe will involve a broader patient population, namely heterozygous FH patients. This strategy ensures that mipomersen will reach the patients who need the drug the most first, and provide commercial experience with mipomersen as we broaden our indication to larger patient populations, such as heterozygous FH patients. We have now completed enrollment in the mipomersen Phase 3 study in heterozygous FH patients, the second of our four Phase 3 studies, and we expect to report the data from this study in the first half of 2010," continued Ms. Parshall.

"During the last quarter, we and our partners participated prominently in several scientific conferences, including ASCO and ADA, highlighting the versatility and broad applicability of antisense drugs to inhibit targets that could offer new avenues to treat disease, including cancer and type 2 diabetes. In addition to our clinical programs, we have active programs in many different therapeutic areas as well as established academic relationships with industry and academic leaders that expand our research capabilities. With the efficiency of our drug discovery technology we can broadly evaluate and conduct preliminary research on a vast array of new targets, so that we can add new drugs to our pipeline each year," added Ms. Parshall.

"In summary, it has been an eventful and promising first half of the year. Our financial position ensures that we can continue to invest our resources in filling the pipeline and continuing to move our drugs forward toward the market. We have the technology, the expertise and the momentum to realize the full potential of antisense as a drug discovery technology," concluded Ms. Parshall.

Drug Development Highlights

Mipomersen
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced today that Sergio Traversa , chief ... MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December ... Luxe Sunset Bel Air Hotel, which is located at ... . The presentation is scheduled for ...
(Date:11/24/2014)... , Nov. 24, 2014  AiCure, an artificial ... technology to monitor medication ingestion, has announced the ... and intervene with patients receiving medication as maintenance ... overdoses from prescription opiates have quadrupled in the ... per year than heroin, cocaine and benzodiazepines combined. ...
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Can artificial intelligence solve the $55 billion problem of opioid abuse? 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
(Date:11/23/2014)... 2014 Tbdress.com has recently announced ... on Nov. 28, 2014. The special offer will provide ladies ... is one of the world’s largest women’s dresses retailers, and ... People can enjoy great discounts on that day: Everything at ... delivery (for orders above $89). , People can use the ...
(Date:11/23/2014)... 2014 (HealthDay News) -- Close friends have more influence ... does, a new study says. "We,ve known ... an influence on individual alcohol use, but there are ... group and the friend group,s influence on those decisions," ... of Public Health, said in a university news release. ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... “BlackVue” was featured on NewsWatch as part of ... latest and coolest technology products available to consumers. Mallory ... the product review and shared with viewers how their ... car camera industry. , The need for in-car video ... find the one that’s right per consumer, especially considering ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... Patients with obstructive sleep apnea (OSA) who ... of continuous positive airway pressure (CPAP) relieves them of ... the October 15 issue of the Journal of Clinical ... The Sleep Center at Universitys Community Hospital in Tampa, ...
... published in the October 15 issue of the Journal ... Sleepiness Questionnaire (CASQ), a new self-completed instrument to measure ... by James C. Spilsbury, PhD, of the Division of ... a subsample of 411 adolescents between 11-17 years of ...
... France, October 15 Sanofi Pasteur, the,vaccines ... partnership,with Institut Pasteur to develop a vaccine ... will have access to antigens,identified by Institut ... for the most deadly malaria infections. Sanofi ...
... SEATTLE, October 15 - ,Real Women, Real ... Recognition and Treatment in Women Around the World ... (IASP) has,declared 2008 the Global Year Against Pain in ... pain on women and the need for more,effective care. ...
... leading cancer organizations shows cancer death rates decreased on ... nearly twice the annual decrease of 1.1 percent per ... in the Annual Report to the Nation on the ... and Alaska Natives published online October 15, 2007 ( ...
... One of the most distressing aspects of Alzheimer,s disease is ... beginning of an inevitable mental decline. Researchers at the Stanford ... is a step toward giving people an answer two to ... , The test identifies changes in a handful of proteins ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 3Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 2Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 3Health News:Annual report to the nation finds cancer death rate decline doubling 2Health News:Annual report to the nation finds cancer death rate decline doubling 3Health News:Annual report to the nation finds cancer death rate decline doubling 4Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 2Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 3Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: